
Preclinical tests support FGFR3 inhibitor in skeletal dysplasia
Biotechnology company Tyra Biosciences has announced preclinical proof-of-concept results with TYRA-300, an investigational oral fibroblast growth factor receptor 3 (FGFR3) selective inhibitor, in hypochondroplasia (HCH). The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference (Pharmachon 2024). HCH is a… Read More
